Durability of response among patients with psoriatic arthritis (PsA) using biological or targeted synthetic disease-modifying antirheumatic drugs in the CorEvitas PsA/spondyloarthritis registry

Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension